The decision to discontinue the development of fezagepras is based on results from the Phase 1a single ascending dose ("SAD") clinical trial, which indicated that fezagepras was significantly inferior compared to Sodium Phenylbutyrate as a nitrogen scavenger. The Phase 1a SAD clinical trial of fezagepras initiated in May 2022 was designed as a head-to-head comparison with Sodium Phenylbutyrate to provide us with further data to determine whether fezagepras was worth developing for one of the potential indications where nitrogen scavenging is beneficial. The recommendation to stop the development program for fezagepras was not based on safety concerns.

"We have come to this decisive, data driven conclusion early in Q3 in line with previously issued guidance," stated Bruce Pritchard, Chief Executive Officer of Liminal BioSciences. "This allows us to focus our resources on our preclinical development programs. We look forward to updating the market on our expected milestones for our GPR84 and OXER1 antagonists' preclinical candidates targeting inflammatory, metabolic, and fibrotic conditions. In addition to these programs, we continue to explore other development opportunities to add to our pipeline."